Non-Alcoholic Fatty Liver DiseaseSymptoms, Doctors, Treatments, Advances & More
Learn About Non-Alcoholic Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition that is characterized by a buildup of fat in the liver, which can lead to liver damage. The liver is part of the digestive system, and it helps break down food, store energy, and remove waste products. If more than 5 percent of the liver contains fat, the liver is considered to be fatty (steatotic).
The specific causes of MASLD are unclear, although this condition is likely a result of both environmental factors and changes in several genes. Genetic changes that increase the risk of disease are called pathogenic variants.
Common conditions include: Nonalcoholic Steatohepatitis (NASH)
MASLD occurs in about 25 percent adults and 7 to 14 percent of children worldwide. It is the most common chronic liver disorder in Western countries, including the United States, and its prevalence is increasing along with the rising prevalence of obesity. It is estimated that MASLD will affect over half of individuals by 2040.
An increased risk of developing MASLD can be passed down through generations in families, but the inheritance pattern is unknown.
Banner - University Medicine Transplant Institute
I love running, traveling to the new places, and watching sports. Dr. Wijarnpreecha is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Non-Alcoholic Fatty Liver Disease, Cirrhosis, Malabsorption, Liver Transplant, and Kidney Transplant. Dr. Wijarnpreecha is board certified in American Board Of Internal Medicine/Gastroenterology, American Board Of Internal Medicine, and American Board Of Internal Medicine/Transplant Hepatology. Dr. Wijarnpreecha is currently accepting new patients.
Cleveland Clinic Main Campus
Srinivasan Dasarathy is a Transplant Surgeon practicing medicine in Cleveland, Ohio. Dr. Dasarathy is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Non-Alcoholic Fatty Liver Disease, Liver Failure, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy. Dr. Dasarathy is board certified in American Board Of Internal Medicine, 2008.
Northwell Health Physician Partners Sandra Atlas Bass Center For Liver Diseases
Dr. Sanjaya K. Satapathy is the medical director of the Center for Liver Disease and Transplantation at the Northwell Transplant Institute, program director of Northwell's Transplant Hepatology Fellowship, and professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.His path to medicine began in India, where he was inspired by his father an engineer with a passion for homeopathy to pursue a career in healthcare. He earned his medical degree from Veer Surendra Sai Medical College, followed by fellowship training in gastroenterology and hepatology in the early 2000s. During that time, he witnessed the profound need for liver transplantation in India, where access remained scarce.While presenting his research at a conference in the United States, Dr. Satapathy was drawn to the opportunities and possibilities for advancing transplantation in America. He decided to continue his career in the United States, completing additional residency and fellowship training before serving as a transplant hepatologist in Memphis. In 2019, he was recruited to Northwell.It was a dream to begin from zero and build a transplant program that could be a model not just for the area or the state, but for the country, says Dr. Satapathy. Within only a few years, we've been able to achieve that goal, because Northwell has all the elements and resources to be one of the best programs in the nation. The expertise we have is unparalleled, with a collaborative team that encompasses all levels of care.The program was founded just in time for a huge surge in demand for liver transplants in the area, he adds. Liver disease and other liver issues are on the rise, making the need for an extensive program crucial for those in the New York region. Part of the program's strength is innovation. For example, Northwell is utilizing an approach that allows donated organs to be safely preserved for a longer period of time, which means needed organs can travel longer distances even from as far away as Hawaii. Northwell is also running several clinical trials on transplant medications and operates a robust transplant hepatology fellowship program to train the next generation of doctors a program Dr. Satapathy launched.I'm passionate about this work, and particularly about my patients, he says. I see every patient as my family, and my focus is on what I can do next to help them. Dr. Satapathy is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Spontaneous Bacterial Peritonitis, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy. Dr. Satapathy is board certified in American Board Of Internal Medicine, American Board Of Internal Medicine/Gastroenterology, and American Board Of Internal Medicine/Transplant Hepatology.
Summary: Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk ...
Summary: The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.
Published Date: April 01, 2026
Published By: National Institutes of Health